NK cells: Tuned by peptide?

Immunological Reviews

Volumn 267, Issue 1, 2015, Pages 214-227

  Das, Jayajit ^a   Khakoo, Salim I ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

CD94; KIR; Natural killer cells; NKG2A; Viral infection

Indexed keywords

ALANINE; CD94 ANTIGEN; EPITOPE; GLYCINE; HETERODIMER; HLA C ANTIGEN; HLA E ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; LECTIN; LYMPHOCYTE RECEPTOR; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2C; NATURAL KILLER CELL RECEPTOR NKG2E; RNA DIRECTED RNA POLYMERASE; SERINE; SIGNAL PEPTIDE; THREONINE; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; LIGAND; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; PEPTIDE; PROTEIN BINDING;

ARTICLE; BALANCING SELECTION; CELL INTERACTION; CELL SURFACE; CONTROLLED CLINICAL TRIAL (TOPIC); GENE LOCUS; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR TYPING; NATURAL KILLER CELL; NEGATIVE FEEDBACK; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; VIRUS INFECTION; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY; METABOLISM;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LIGANDS; MODELS, IMMUNOLOGICAL; PEPTIDES; PROTEIN BINDING; RECEPTORS, KIR; RECEPTORS, NK CELL LECTIN-LIKE;

EID: 84939515843     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12315     Document Type: Article

References (153)

1. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-678.
2. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990;11:237-244.
3. Bukowski JF, Warner JF, Dennert G, Welsh RM. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J Exp Med 1985;161:40-52.
4. Scalzo AA, Fitzgerald NA, Simmons A, La Vista AB, Shellam GR. Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J Exp Med 1990;171:1469-1483.
5. Salazar-Mather TP, Orange JS, Biron CA. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med 1998;187:1-14.
6. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002;296:1323-1326.
7. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989;320:1731-1735.
8. Vidal SM, Khakoo SI, Biron CA. Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience. Curr Opin Virol 2011;1:497-512.
9. Artavanis-Tsakonas K, et al. Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes. J Immunol 2003;171:5396-5405.
10. Yarovinsky F. Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol 2014;14:109-121.
11. Bogdan C. Natural killer cells in experimental and human leishmaniasis. Front Cell Infect Microbiol 2012;2:69.
12. Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013;13:133-144.
13. Newman KC, Korbel DS, Hafalla JC, Riley EM. Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria. PLoS Pathog 2006;2:e118.
14. Baratin M, et al. Natural killer cell and macrophage cooperation in MyD88-dependent innate responses to Plasmodium falciparum. Proc Natl Acad Sci USA 2005;102:14747-14752.
15. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002;195:343-351.
16. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-333.
17. Moretta A. The dialogue between human natural killer cells and dendritic cells. Curr Opin Immunol 2005;17:306-311.
18. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2012;481:394-398.
19. Peppa D, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 2013;210:99-114.
20. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009;457:557-561.
21. O'Leary JG, Goodarzi M, Drayton DL, von Andrian UH. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol 2006;7:507-516.
22. + NK cells. J Immunol 2015;194:2467-2471.
23. Sun JC, Ugolini S, Vivier E. Immunological memory within the innate immune system. EMBO J 2014;33:1295-1303.
24. Knapp LA, Cadavid LF, Watkins DI. The MHC-E locus is the most well conserved of all known primate class I histocompatibility genes. J Immunol 1998;160:189-196.
25. Adams EJ, Parham P. Species-specific evolution of MHC class I genes in the higher primates. Immunol Rev 2001;183:41-64.
26. Carretero M, et al. The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur J Immunol 1997;27:563-567.
27. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 1998;8:693-701.
28. Braud VM, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795-799.
29. Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol 1997;27:1164-1169.
30. Brooks AG, Posch PE, Scorzelli CJ, Borrego F, Coligan JE. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J Exp Med 1997;185:795-800.
31. Lee N, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998;95:5199-5204.
32. Vance RE, Jamieson AM, Raulet DH. Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J Exp Med 1999;190:1801-1812.
33. Vance RE, Kraft JR, Altman JD, Jensen PE, Raulet DH. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J Exp Med 1998;188:1841-1848.
34. Llano M, et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998;28:2854-2863.
35. Cheent KS, et al. Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94. Proc Natl Acad Sci USA 2013;110:16981-16986.
36. Valiante NM, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997;7:739-751.
37. Brutkiewicz RR, Klaus SJ, Welsh RM. Window of vulnerability of vaccinia virus-infected cells to natural killer (NK) cell-mediated cytolysis correlates with enhanced NK cell triggering and is concomitant with a decrease in H-2 class I antigen expression. Nat Immun 1992;11:203-214.
38. Seet BT, et al. Poxviruses and immune evasion. Annu Rev Immunol 2003;21:377-423.
39. Brooks CR, Elliott T, Parham P, Khakoo SI. The inhibitory receptor NKG2A determines lysis of vaccinia virus-infected autologous targets by NK cells. J Immunol 2006;176:1141-1147.
40. Tomasec P, et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000;287:1031.
41. Ulbrecht M, et al. Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol 2000;164:5019-5022.
42. Heatley SL, et al. Polymorphism in human cytomegalovirus UL40 impacts on recognition of human leukocyte antigen-E (HLA-E) by natural killer cells. J Biol Chem 2013;288:8679-8690.
43. Stevens J, Joly E, Trowsdale J, Butcher GW. Peptide binding characteristics of the non-classical class Ib MHC molecule HLA-E assessed by a recombinant random peptide approach. BMC Immunol 2001;2:5.
44. Lampen MH, et al. Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol Immunol 2013;53:126-131.
45. Nattermann J, et al. HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir Ther 2005;10:95-107.
46. Nattermann J, et al. The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol 2005;166:443-453.
47. Ulbrecht M, Modrow S, Srivastava R, Peterson PA, Weiss EH. Interaction of HLA-E with peptides and the peptide transporter in vitro: implications for its function in antigen presentation. J Immunol 1998;160:4375-4385.
48. Petrie EJ, et al. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence. J Exp Med 2008;205:725-735.
49. Kaiser BK, Pizarro JC, Kerns J, Strong RK. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci USA 2008;105:6696-6701.
50. + NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus. J Immunol 2014;192:4492-4496.
51. Naluyima P, et al. Impaired natural killer cell responses are associated with loss of the highly activated NKG2A(+)CD57(+)CD56(dim) subset in HIV-1 subtype D infection in Uganda. AIDS 2014;28:1273-1278.
52. Zhang R, et al. Increased NKG2A found in cytotoxic natural killer subset in HIV-1 patients with advanced clinical status. AIDS 2007;21(Suppl 8):S9-S17.
53. Merino AM, Sabbaj S, Easlick J, Goepfert P, Kaslow RA, Tang J. Dimorphic HLA-B signal peptides differentially influence HLA-E- and natural killer cell-mediated cytolysis of HIV-1-infected target cells. Clin Exp Immunol 2013;174:414-423.
54. Thoens C, et al. KIR2DL3(+)NKG2A(-) natural killer cells are associated with protection from productive hepatitis C virus infection in people who inject drugs. J Hepatol 2014;61:475-481.
55. Golden-Mason L, et al. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 2008;57:1121-1128.
56. Bonorino P, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 2009;51:458-467.
57. Harrison RJ, Ettorre A, Little AM, Khakoo SI. Association of NKG2A with treatment for chronic hepatitis C virus infection. Clin Exp Immunol 2010;161:306-314.
58. Werner JM, et al. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection. Hepatology 2013;58:1621-1631.
59. Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J 1999;18:4250-4260.
60. Kaiser BK, Barahmand-Pour F, Paulsene W, Medley S, Geraghty DE, Strong RK. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol 2005;174:2878-2884.
61. Saez-Borderias A, Romo N, Magri G, Guma M, Angulo A, Lopez-Botet M. IL-12-dependent inducible expression of the CD94/NKG2A inhibitory receptor regulates CD94/NKG2C+ NK cell function. J Immunol 2009;182:829-836.
62. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004;104:3664-3671.
63. Rolle A, et al. IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. J Clin Invest 2014;124:5305-5316.
64. Bjorkstrom NK, et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011;208:13-21.
65. Petitdemange C, et al. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog 2011;7:e1002268.
66. Beziat V, et al. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol 2012;42:447-457.
67. Goodier MR, Mela CM, Steel A, Gazzard B, Bower M, Gotch F. NKG2C+ NK cells are enriched in AIDS patients with advanced-stage Kaposi's sarcoma. J Virol 2007;81:430-433.
68. Fang M, Orr MT, Spee P, Egebjerg T, Lanier LL, Sigal LJ. CD94 is essential for NK cell-mediated resistance to a lethal viral disease. Immunity 2011;34:579-589.
69. Orbelyan GA, et al. Human NKG2E is expressed and forms an intracytoplasmic complex with CD94 and DAP12. J Immunol 2014;193:610-616.
70. Nachmani D, et al. MicroRNA editing facilitates immune elimination of HCMV infected cells. PLoS Pathog 2014;10:e1003963.
71. Uhrberg M, et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997;7:753-763.
72. Yawata M, et al. Predominance of group A KIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression. Immunogenetics 2002;54:543-550.
73. John E, et al. Distinct distribution of killer-cell immunoglobulin-like receptor genes in the Mugil and Ilaita areas of Papua New Guinea. Tissue Antigens 2012;79:263-271.
74. Norman PJ, et al. Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans. PLoS Genet 2013;9:e1003938.
75. Hadler SC, et al. Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela. Ann Intern Med 1984;100:339-344.
76. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 2008;112:2369-2380.
77. Gendzekhadze K, et al. Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. Proc Natl Acad Sci USA 2009;106:18692-18697.
78. Zhi-ming L, et al. Polymorphisms of killer cell immunoglobulin-like receptor gene: possible association with susceptibility to or clearance of hepatitis B virus infection in Chinese Han population. Croat Med J 2007;48:800-806.
79. Dring MM, et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci USA 2011;108:5736-5741.
80. de Vasconcelos JM, et al. Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil. Genet Mol Biol 2013;36:22-27.
81. Wauquier N, Padilla C, Becquart P, Leroy E, Vieillard V. Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection. Immunogenetics 2010;62:767-771.
82. Augusto DG, Hollenbach JA, Petzl-Erler ML. A deep look at KIR-HLA in Amerindians: comprehensive meta-analysis reveals limited diversity of KIR haplotypes. Hum Immunol 2015;76:272-280.
83. Nakimuli A, et al. A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia. Proc Natl Acad Sci USA 2015;112:845-850.
84. Hiby SE, et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest 2010;120:4102-4110.
85. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002;20:217-251.
86. Stewart CA, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005;102:13224-13229.
87. O'Connor GM, et al. Peptide-dependent recognition of HLA-B*57:01 by KIR3DS1. J Virol 2015;89:5213-5221.
88. David G, et al. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation. J Immunol 2013;191:4778-4788.
89. Liu J, Xiao Z, Ko HL, Shen M, Ren EC. Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11. Proc Natl Acad Sci USA 2014;111:2662-2667.
90. Pende D, et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med 1996;184:505-518.
91. Graef T, et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med 2009;206:2557-2572.
92. Hansasuta P, et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 2004;34:1673-1679.
93. Dohring C, Scheidegger D, Samaridis J, Cella M, Colonna M. A human killer inhibitory receptor specific for HLA-A. J Immunol 1996;156:3098-3101.
94. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008;180:3969-3979.
95. Maenaka K, et al. Killer cell immunoglobulin receptors and T cell receptors bind peptide-major histocompatibility complex class I with distinct thermodynamic and kinetic properties. J Biol Chem 1999;274:28329-28334.
96. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol 1998;161:571-577.
97. Pende D, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009;113:3119-3129.
98. Schonberg K, Sribar M, Enczmann J, Fischer JC, Uhrberg M. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 2011;117:98-107.
99. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 2000;405:537-543.
100. Fan QR, Long EO, Wiley DC. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol 2001;2:452-460.
101. Vivian JP, et al. Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature 2011;479:401-405.
102. Khakoo SI, Geller R, Shin S, Jenkins JA, Parham P. The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer. J Exp Med 2002;196:911-921.
103. Kumar S, Sarkar P, Sim MJ, Rajagopalan S, Vogel SS, Long EO. A single amino acid change in inhibitory killer cell Ig-like receptor results in constitutive receptor self-association and phosphorylation. J Immunol 2015;194:817-826.
104. Malnati MS, et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 1995;267:1016-1018.
105. Peruzzi M, Parker KC, Long EO, Malnati MS. Peptide sequence requirements for the recognition of HLA-B*2705 by specific natural killer cells. J Immunol 1996;157:3350-3356.
106. Rajagopalan S, Long EO. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J Exp Med 1997;185:1523-1528.
107. Zappacosta F, Borrego F, Brooks AG, Parker KC, Coligan JE. Peptides isolated from HLA-Cw*0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc Natl Acad Sci USA 1997;94:6313-6318.
108. Mandelboim O, Wilson SB, Vales-Gomez M, Reyburn HT, Strominger JL. Self and viral peptides can initiate lysis by autologous natural killer cells. Proc Natl Acad Sci USA 1997;94:4604-4609.
109. Thananchai H, et al. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007;178:33-37.
110. Maloveste SM, et al. Degenerate recognition of MHC class I molecules with Bw4 and Bw6 motifs by a killer cell Ig-like receptor 3DL expressed by macaque NK cells. J Immunol 2012;189:4338-4348.
111. Fadda L, et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci USA 2010;107:10160-10165.
112. Barber LD, et al. The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C. J Exp Med 1996;184:735-740.
113. Borhis G, et al. A peptide antagonist disrupts NK cell inhibitory synapse formation. J Immunol 2013;190:2924-2930.
114. Beltrame LM, et al. Influence of KIR genes and their HLA ligands in susceptibility to dengue in a population from southern Brazil. Tissue Antigens 2013;82:397-404.
115. Sumen C, Dustin ML, Davis MM. T cell receptor antagonism interferes with MHC clustering and integrin patterning during immunological synapse formation. J Cell Biol 2004;166:579-590.
116. Lyons DS, et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 1996;5:53-61.
117. Standeven LJ, Carlin LM, Borszcz P, Davis DM, Burshtyn DN. The actin cytoskeleton controls the efficiency of killer Ig-like receptor accumulation at inhibitory NK cell immune synapses. J Immunol 2004;173:5617-5625.
118. Lorenz U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev 2009;228:342-359.
119. Rajagopalan S, Long EO. Antagonizing inhibition gets NK cells going. Proc Natl Acad Sci USA 2010;107:10333-10334.
120. O'Connor GM, McVicar D. The yin-yang of KIR3DL1/S1: molecular mechanisms and cellular function. Crit Rev Immunol 2013;33:203-218.
121. Cassidy S, et al. Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals. Eur J Immunol. 2015;45:492-500.
122. Hansen TH, Bouvier M. MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol 2009;9:503-513.
123. Cifaldi L, et al. ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors. Cancer Res 2015;75:824-834.
124. Yewdell JW, Nicchitta CV. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol 2006;27:368-373.
125. de Verteuil D, Granados DP, Thibault P, Perreault C. Origin and plasticity of MHC I-associated self peptides. Autoimmun Rev 2012;11:627-635.
126. Bourdetsky D, Schmelzer CE, Admon A. The nature and extent of contributions by defective ribosome products to the HLA peptidome. Proc Natl Acad Sci USA 2014;111:E1591-E1599.
127. Anton LC, Yewdell JW. Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors. J Leukoc Biol 2014;95:551-562.
128. Granados DP, et al. MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements. Blood 2012;119:e181-e191.
129. Powdrill MH, et al. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci USA 2011;108:20509-20513.
130. Khan S, et al. Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J Immunol 2001;167:4801-4804.
131. Trujillo JA, et al. The cellular redox environment alters antigen presentation. J Biol Chem 2014;289:27979-27991.
132. Hickman HD, et al. Cutting edge: class I presentation of host peptides following HIV infection. J Immunol 2003;171:22-26.
133. Wahl A, Schafer F, Bardet W, Hildebrand WH. HLA class I molecules reflect an altered host proteome after influenza virus infection. Hum Immunol 2010;71:14-22.
134. van Els CA, et al. A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur J Immunol 2000;30:1172-1181.
135. Croft NP, et al. Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog 2013;9:e1003129.
136. Liberatore C, et al. Natural killer cell-mediated lysis of autologous cells modified by gene therapy. J Exp Med 1999;189:1855-1862.
137. Alter G, et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 2011;476:96-100.
138. Berglund P, Finzi D, Bennink JR, Yewdell JW. Viral alteration of cellular translational machinery increases defective ribosomal products. J Virol 2007;81:7220-7229.
139. Mohr I, Sonenberg N. Host translation at the nexus of infection and immunity. Cell Host Microbe 2012;12:470-483.
140. Larance M, Ahmad Y, Kirkwood KJ, Ly T, Lamond AI. Global subcellular characterization of protein degradation using quantitative proteomics. Mol Cell Proteomics 2013;12:638-650.
141. Achdout H, Manaster I, Mandelboim O. Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins. J Virol 2008;82:8030-8037.
142. Lev A, et al. Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action. Proc Natl Acad Sci USA 2010;107:6964-6969.
143. Khakoo SI, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004;305:872-874.
144. Romero V, et al. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Mol Immunol 2008;45:2429-2436.
145. Vidal-Castineira JR, et al. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 2010;84:475-481.
146. Marangon AV, et al. KIR genes and their human leukocyte antigen ligands in the progression to cirrhosis in patients with chronic hepatitis C. Hum Immunol 2011;72:1074-1078.
147. Nozawa Y, et al. KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan. PLoS ONE 2013;8:e83381.
148. Ahlenstiel G, Martin MP, Gao X, Carrington M, Rehermann B. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest 2008;118:1017-1026.
149. Martin MP, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002;31:429-434.
150. O'Connor GM, et al. Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity. J Immunol 2014;192:2875-2884.
151. Gardiner CM, et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001;166:2992-3001.
152. Martin MP, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007;39:733-740.
153. Apps R, Meng Z, Del Prete GQ, Lifson JD, Zhou M, Carrington M. Relative expression levels of the HLA class-I proteins in normal and HIV infected cells. J Immunol 2015;194:3594-600.